Acadia Pharmaceuticals (ACAD) Q4 Earnings Lag Estimates

Core Viewpoint - Acadia Pharmaceuticals reported quarterly earnings of $0.17 per share, missing the Zacks Consensus Estimate of $0.19 per share, and showing a decline from $0.28 per share a year ago, indicating an earnings surprise of -10.53% [1] Financial Performance - The company posted revenues of $259.6 million for the quarter ended December 2024, surpassing the Zacks Consensus Estimate by 1.79%, compared to $231.04 million in the same quarter last year [2] - Over the last four quarters, Acadia has exceeded consensus EPS estimates three times and has topped consensus revenue estimates three times as well [2] Stock Performance - Acadia shares have increased by approximately 3.6% since the beginning of the year, outperforming the S&P 500's gain of 1.3% [3] Future Outlook - The company's earnings outlook will be crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The current consensus EPS estimate for the next quarter is $0.14 on revenues of $235.58 million, and for the current fiscal year, it is $0.76 on revenues of $1.04 billion [7] Industry Context - The Medical - Biomedical and Genetics industry, to which Acadia belongs, is currently ranked in the top 24% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8]